Skip to main content

Table 1 Clinical characteristics of patients

From: The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study

  Values (336)
Gender [No. (%)]
 Male 215(64.0)
 Female 121(36.0)
Age [years]
  < =14 223(66.4)
  > 14 113(33.6)
Median (range) 12 (2–55)
Body weight(kg)median(range) 37(10–82)
Disease [No. (%)]
 AML 110(32.7)
 ALL 177(52.7)
 CML 16(4.8)
 MDS 22(6.5)
 Others 11(3.3)
State of disease [No. (%)]
 CR or Chronic phase 257(76.5)
 NR or Advanced phase 79(23.5)
HLA match (low-resolution) [No. (%)]
 4/6 113(33.6)
 5/6 168(50.0)
 6/6 55(16.4)
Conditioning regimen [No. (%)]
 Including TBI 109(32.4)
 Not including TBI 227(67.6)
Total nucleated-cell dose, 107/kg median(range) 4.17(1.71–13.90)
Total CD34+ cell dose, 105/kg median(range) 2.32(0.40–10.55)
  1. AML acute myeloid leukaemia, ALL acute lymphoblastic leukaemia, CML chronic myeloid leukaemia, MDS myelodysplastic syndrome, HLA human leukocyte antigen, TBI total body irradiation, CR complete remission, NR no remission